A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy

Liu, Zhilin; Ren, Xi-Tong; Huang, Yue; Sun, Jiali; Wang, Xiaoshuang; Zheng, Meng-Fei; Cui, Linjie; Zhang, Xuefei; Tang, Zhaohui

doi:10.1007/s10118-023-2921-7

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These side effects could be bypassed by developing a CA4P delivery strategy to increase cellular uptake, and thus bioavailability. Nanomaterials that are effective in shielding the hydrophilicity and electronegativity of phosphate groups have been employed to improve the bioavailability of CA4P by many groups [ 12 , 13 , 14 , 15 , 16 , 17 ]. They showed varying degrees of in vivo improvement in antitumor activity and biosafety compared to those of free CA4P.…”

Section: Introductionmentioning

confidence: 99%

Applying a Tripodal Hexaurea Receptor for Binding to an Antitumor Drug, Combretastatin-A4 Phosphate

Kong,

Zhang,

et al. 2024

Materials

View full text Add to dashboard Cite

Phosphates play a crucial role in drug design, but their negative charge and high polarity make the transmembrane transport of phosphate species challenging. This leads to poor bioavailability of phosphate drugs. Combretastatin-A4 phosphate (CA4P) is such an anticancer monoester phosphate compound, but its absorption and clinical applicability are greatly limited. Therefore, developing carrier systems to effectively deliver phosphate drugs like CA4P is essential. Anion receptors have been found to facilitate the transmembrane transport of anions through hydrogen bonding. In this study, we developed a tripodal hexaurea anion receptor (L1) capable of binding anionic CA4P through hydrogen bonding, with a binding constant larger than 104 M−1 in a DMSO/water mixed solvent. L1 demonstrated superior binding ability compared to other common anions, and exhibited negligible cell cytotoxicity, making it a promising candidate for future use as a carrier for drug delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Applying a Tripodal Hexaurea Receptor for Binding to an Antitumor Drug, Combretastatin-A4 Phosphate

Kong,

Zhang,

et al. 2024

Materials

View full text Add to dashboard Cite

show abstract

“…1,2 In recent years, a large number of researchers have devoted themselves to the experimental and theoretical research on ESIPT. [3][4][5][6][7][8][9][10][11][12] Due to the large Stokes shift, absorption and fluorescence spectrum can effectively avoid interference from other fluorescent materials. The substituent and solvation simulation on ESIPT mechanism of fluorescent molecules have been prevailed in many fields, such as chemical sensor, [13][14][15] molecular switch, 16,17 and laser dye.…”

Section: Introductionmentioning

confidence: 99%

Electronegativity effect on the ESIPT process of 4′‐N,N‐dimethylamino‐3‐hydroxyflavone (DMA3HF) and its derivatives

Liu,

Han,

Wang

et al. 2023

J of Physical Organic Chem

View full text Add to dashboard Cite

Abstract4′‐N,N‐dimethylamino‐3‐hydroxyflavone (DMA3HF) has antioxidant activity and excited state proton transfer (ESIPT) property. In this study, the influence of electronegativity on the ESIPT process has been studied by DFT/TD‐DFT methods. Except DMA3HF, the substitutes of S and Se have been designed. The analysis of main bond parameters, infrared vibration spectra, and reduced density gradient function shows that the reduction of atomic electronegativity could promote the ESIPT process. Dihedral angle, frontier molecular orbitals and hole‐electron analysis indicate that the twisted intramolecular charge transfer (TICT) process has been enhanced by the decreasing electronegativity. The results show that the decrease of atomic electronegativity is beneficial to TICT and ESIPT processess.

show abstract

“…24 Specifically, the monofunctional VDAs-nanoparticles, poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4 (C-NPs) have a low intratumoral permeability, resulting in excellent tumor vascular-targeting capability. [25][26][27][28][29] Furthermore, monotherapy of C-NPs could induce the polarization of tumor-associated macrophages (TAMs) toward the M2-like phenotype (M2-TAMs) and increase the infiltration of M2-TAMs, which may subsequently lead to tumor recurrence after treatment. [30][31][32] Therefore, the highly selective small molecular inhibitor of colonystimulating factor receptor (CSF-1R) kinase, BLZ945, can be covalently bound to poly(L-glutamic acid) together with CA4 to obtain CB-NPs.…”

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Guo,

Huang,

Wang

et al. 2023

IJN

Self Cite

View full text Add to dashboard Cite

Cervical cancer (CC) is a highly vascularized tumor with abundant abnormal blood vessel, which could be targeted by therapeutic strategies. Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential as nano vascular disrupting agents (VDAs) in the realm of synergistic cancer therapy. Methods: In this study, we investigated the nanocharacteristics of CB-NPs, focusing on active pharmaceutical ingredients (API), as well as lyophilized samples combining API with protective agents (PAs). The in vivo efficacy of final sample (API + PAs) was evaluated. Results:The assembled sphere of API with complex core and thin-shell structure was confirmed. PAs were found to significantly influence in vivo efficacy. Collaborative efforts between API and PAs, namely mannitol and lactose, resulted in the most promising lyophilized sample, ie, the final sample (FS2) for CC therapy. Impressively, FS2 demonstrated an exceptional 100% cure rate on the CC U14-bearing mice model. Conclusion: FS2 has provided significant insights for cervical cancer therapy. It is also crucial to develop a comprehensive evaluation strategy for the formulation of nanomedicine, which has the potential to serve as a guideline for future clinical trials.

show abstract

A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy

Cited by 5 publications

References 28 publications

Applying a Tripodal Hexaurea Receptor for Binding to an Antitumor Drug, Combretastatin-A4 Phosphate

Applying a Tripodal Hexaurea Receptor for Binding to an Antitumor Drug, Combretastatin-A4 Phosphate

Electronegativity effect on the ESIPT process of 4′‐N,N‐dimethylamino‐3‐hydroxyflavone (DMA3HF) and its derivatives

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Contact Info

Product

Resources

About